Heart attacks and strokes are among the leading causes of death globally, with millions suffering from cardiovascular diseases (CVD) every year. There are more than seven million people in the UK alone, with about 100,000 patients experiencing heart attacks annually. However, a group of researchers at University College London (UCL) estimate that one 'polypill' taken daily day could eliminate a majority of these cases dramatically lowering death tolls.

The proposed polypill, a combination of a statin and three blood pressure-lowering drugs, has been under study for over two decades. Experts argue that introducing this pill universally for individuals aged 50 and above could be more effective than the current NHS Health Check, which assesses risk factors every five years for those aged between 40 and 74.

Studies have repeatedly proven the effectiveness of the polypill in preventing CVD. A groundbreaking 2019 study in The Lancet found that five years' use of the polypill cut the risk of heart attack and stroke by a third. In addition, previous modelling analyses have estimated that if given universally to people over 55, the polypill might be able to prevent 80% of heart attacks and strokes.

Today, the NHS Health Check follows a risk-based model in which patients are tested for CVD risk factors and treated with drugs accordingly. Yet, as per UCL's study, this system has serious flaws:

Low Uptake: Just 40% of those eligible for the NHS Health Check choose to have it, leaving a considerable number of at-risk patients undiagnosed and untreated.

Ineffective Prediction of Risk: The majority of heart attacks and strokes happen to people at average risk levels, thus making it challenging to identify the need for intervention effectively.

Limited Effectiveness: Even at maximum take-up, the NHS Health Check programme is predicted to have fewer health impacts compared to a polypill initiative applied to the whole population.

Simplicity and Affordability of the Polypill Strategy

One of the big benefits of the polypill is that it is so easy. In contrast to the existing screening-based model, the polypill scheme would not involve complicated medical tests or lengthy risk assessments. Instead, people reaching 50 would just have to fill out a few questions to determine possible side effects before they were prescribed.

Professor Aroon Hingorani of the UCL Institute of Cardiovascular Science, one of the strongest proponents of this scheme, says:

"Finally, the time is now to do much better on prevention. A population approach would prevent a lot more heart attacks and strokes than is done today with a strategy of trying to target a smaller group only."

Aside from the possible health implications, the polypill is also an economic solution. The drugs used are off-patent, thus cheap to produce and distribute. With the vast economic cost of managing CVD-related illnesses, a preventive model could result in substantial cost-saving for the NHS in the future.

The polypill has been proven to be effective by numerous international trials. In 2019, a randomised trial in rural Iran discovered that participants who took the polypill for five years had a 34% reduced risk of having a heart attack or stroke compared to non-participants.

Likewise, modelling research has indicated that even if only 8% of people aged over 50 took up the polypill regimen, it would still be more beneficial to their health than the NHS Health Check programme.

Is This a Case of Over-Medicalisation?

One of the main objections to the polypill strategy is the suggestion that it might result in the unnecessary medicalisation of a significant proportion of the population. But, it is argued, it should be considered as a preventative measure, not as mass medication.

Professor Sir Nicholas Wald of UCL's Institute of Health Informatics explains:

"Instead of being a 'medicalisation' of a significant proportion of the population, a polypill programme is a prevention measure to prevent an individual from becoming a patient."

He compares it with public health measures like water fluoridation or compulsory seatbelts—interventions that have been shown to have a significant impact in reducing public health danger at low individual cost.

With the evidence in favour of the polypill's effectiveness and viability overwhelming, experts are calling on the NHS to act now. It is their belief that substituting the NHS Health Check with a polypill-based prevention program could be the UK government's flagship policy under its pledge to put disease prevention ahead of cure.

As Professor Hingorani points out, "The status quo is not a justifiable option." With CVD still a major cause of death globally, taking a population-wide polypill approach could be a turning point for preventative medicine, potentially saving thousands of lives annually. The question now is whether the NHS will take up this call and establish a policy with the potential to transform the prevention of cardiovascular disease on a national level.

One in seven stroke patients in India are young adults aged below 45 years, with hypertension leading as the major risk factor, according to a study by the Indian Council of Medical Research (ICMR).

The study, published in the International Journal of Stroke, showed that two in five patients arrived in the hospital after 24 hours of onset of symptoms, highlighting the need for improving awareness about the first hour (golden hour) in stroke care.

“The findings highlight the gaps in acute stroke care, including delayed hospital arrival, limited access to advanced treatments, and inadequate follow-up services,” said Prashant Mathur, Director, ICMR—National Centre for Disease Informatics and Research, Bengaluru, in the paper.

“Stroke continues to pose a major public health burden, with poor outcomes. The study shall contribute to the development of evidence-based comprehensive strategies for stroke prevention, effective management, and improved treatment outcomes,” he added.

What Stroke Patterns Did The Study Find?

The team included 34,792 stroke cases from 30 Hospital-Based Stroke Registries (HBSRs) across India, recorded between 2020 and 2022.

About 64 percent of the stroke patients were males, and 36.6 percent were females.

Stroke in the younger age group (aged below 45 years) constituted 13.8 percent of the total cases. More than 70 per cent of the participants were residents from rural areas.

Hypertension (74.5 percent) was the most common risk factor, followed by smokeless tobacco use (28.5 percent) and diabetes mellitus (27.3 percent).

Ischemic stroke accounted for 60 percent of cases. Only 20.1 percent were presented within 4.5 hours of symptom onset, while 37.8 percent of cases presented after 24 hours.

The commonest symptoms at onset included motor impairment (74.8 percent), followed by speech disturbance (51.2 percent), dysphagia (30.4 percent), and impaired consciousness (25.6 percent).

The study also highlighted substantial disparities in stroke care services. Time-sensitive therapies like thrombolysis were given in 4.6 percent of cases, while thrombectomy was administered in 0.7 percent of ischemic strokes.

At three months, 27.8 percent of patients had died, while nearly 30 percent suffered significant disability, and 1.1 percent had a recurrent stroke. This highlighted the need for improving comprehensive stroke care across India.

Burden Of Stroke In India

Stroke remains one of the leading global health burdens, causing significant deaths and disability worldwide, including in India. Compared to Western countries, stroke also tends to occur at a younger age and is associated with a higher case fatality rate in the country.

The Global Burden of Disease Study 2021 identified hypertension, air pollution, tobacco smoking, high cholesterol, increased salt intake, and diabetes as the leading risk factors of stroke.

Incidence of stroke is increasing significantly in low- and middle-income countries (LMICs), especially in India, due to population growth, aging, and greater exposure to risk factors.

The estimated stroke incidence in India ranged from 108 to 172 per 100,000 population, and 1-month case fatality varied from 18 percent to 42 percent.

As per data from the ICMR-NCDIR, India has a crude stroke incidence rate of 138.1 per 100,000 population and an age-standardized case fatality rate of 30 per 100,000 population.

Amid changing climatic conditions that are soaring temperatures and leading to over 200,000 deaths annually in South Asia, the World Health Organization (WHO) today announced two health initiatives that will prevent the impacts of extreme heat and save lives in the region.

Extreme heat in South Asia, including in India, is rapidly threatening human health and can potentially also cause economic instability in the subcontinent.

The two initiatives -- the South Asia Climate–Health Desk and the South Asia Scientific Research Consortium -- were announced at the ongoing Mumbai Climate Week in collaboration with several global and regional partners.

The initiatives, with an investment of $11.5 million by the Rockefeller Foundation and Wellcome, aim to connect climate science to health action to prevent heat-related deaths and illnesses.

“Few regions feel the impacts of extreme heat as sharply as South Asia, and I welcome the clear determination to respond. We all know that every death primarily due to excess heat can be prevented, and heat health action plans are saving lives,” said Celeste Saulo, Secretary-General at the World Meteorological Organization (WMO) Climate and Health Joint Programme.

“By uniting science, government leadership and support, and community action, countries here are proving that this challenge can be met,” Saulo added.

What Are The 2 Health Initiatives?

The South Asia Climate–Health Desk, implemented with the Indian Institute of Tropical Meteorology (IITM), India Meteorological Department (IMD), aims to improve how climate and weather information is translated into action to protect health.

It is one of the first units under the joint program to embrace research and development and operational domains in climate and health, and will also help develop more robust decision support tools, such as early warning and risk assessments.

The South Asia Scientific Research Consortium, under the Indian Institute of Science Education and Research (IISER) Pune, is expected to deepen the region’s scientific understanding of how heat affects different populations.

By developing tailored heat‑risk thresholds, this consortium aims to ultimately strengthen heat action planning, early warning systems, and preparedness efforts, helping communities and institutions better adapt to rising temperatures.

The Risks Of A Warming South Asia

UN Secretary-General António Guterres has called for urgent global action to address the growing risk of extreme heat worldwide, which takes a heavy toll on health in South Asia – the world’s most populous region.

According to WMO, Asia is warming nearly twice as fast as the global average, intensifying extreme weather and placing growing pressure on lives and livelihoods, health systems, economies, and ecosystems across the region, putting the most vulnerable and exposed communities at critical risk.

In India, pre-monsoon temperatures regularly rise above 50 degrees Celsius, with heat-related mortality exceeding 200,000 deaths per year.

Extreme heat also undermines economic stability and productivity.

In 2024 alone, heat exposure in India led to 247 billion potential labor hours lost. The Lancet Countdown reported that the reduced labor capacity led to an estimated $194 billion loss in income.

Haryana has significantly stepped up its HIV prevention and treatment efforts this year, screening more than 12.4 lakh people and expanding services across the state. Officials say the focus is not only on detection but also on reducing stigma and ensuring patients receive timely care.

Large scale testing across the state

Between April 2025 and January 2026, authorities tested 12,40,205 samples for HIV. Out of these, 5,877 people were found positive.

According to Additional Chief Secretary (Health) Sumita Misra, the state has been strengthening its response by making testing widely available and free. Haryana currently runs 104 integrated counselling and testing centres, including a mobile testing unit in Faridabad. These centres offer confidential screening so people can get tested without fear or hesitation.

A major focus has also been on preventing transmission from mother to child. During the same period, 5,65,830 pregnant women were screened. Among them, 613 tested positive and were immediately linked to treatment to reduce the risk of passing the infection to newborns.

Expanding treatment access

Alongside testing, treatment facilities have also grown. Haryana now operates 24 anti retroviral therapy centres in cities such as Rohtak, Gurugram, Faridabad, Karnal, Hisar, Ambala and Mewat. Thirteen of these centres were recently set up inside medical colleges to improve accessibility.

The state also runs five facility integrated ART centres and four link ART centres. At present, 40,851 patients are receiving HIV treatment across Haryana.

To support patients financially, the government introduced a monthly assistance scheme in December 2021. People living with HIV receive Rs 2,250 every month. So far, Rs 54.3 crore has been distributed under the programme.

Reaching vulnerable communities

The state is also tackling sexually transmitted infections through 31 dedicated clinics that provide free counselling, testing for syphilis, and treatment.

Beyond hospitals, outreach teams are working directly with high risk groups. Forty two targeted intervention projects run by Red Cross societies and NGOs engage with female sex workers, men who have sex with men, intravenous drug users, truck drivers, and migrant laborers.

For people dependent on opioids, Haryana operates 12 opioid substitution therapy centres and three satellite units. A total of 9,014 patients are registered and around 4,570 receive regular treatment.

Officials say several government departments are also involved in awareness programmes to educate communities and reduce stigma, which remains one of the biggest barriers to early testing and consistent treatment.

What IS HIV?

HIV- also referred as the human immunodeficiency disease, is a virus that attack cells of an individual’s immune system, and overtime makes the immune system weak, hence it loses its capability to fight against ordinary diseases, which in return increases the risk of catching up with infections and tumours. An individual is likely to develop AIDS in nearly 8 to 10 years, if HIV is left untreated. AIDS is considered as the final stage of HIV. This chronic disease can cause complications. Read to know more.

Symptoms for HIV

HIV symptoms can vary among individuals. The initial symptoms are Fever, sickness which is same as viral infections. Symptoms include:

• Fever
• Sore throat
• fatigue
• Swollen lymph nodes
• Headache
• Skin rash
• Pneumonia
• Nausea
• Vomiting
• Weight loss
• Weakness
• Skin rashes or bumps
• Night sweats
• Diarrhoea

Every person might experience the same symptoms, many individuals might go through some completely different set of symptoms. Since, the symptoms vary from person- to- person, many people can start noticing these symptoms at earliest stages and most of them aren’t even aware about any of this.